AbuMweis

Behall

Biörklund

Bourdon

Denke

Dongowski

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

Gordon

Ikegami

Keenan

Keogh

Lupton

McIntosh

Newman

Ornish

Pedersen

Rondanelli

Shimizu

Smith

Sundberg

Talati

Van Horn

Wood

Zhang

EFSA Journal

Following an application from Nordic Sugar A/S, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Denmark, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim based on newly developed scientific evidence related to sugar beet fibre and “decreasing intestinal transit time”. The food constituent that is the subject of the health claim is sugar beet fibre. This opinion applies to sugar beet fibre naturally present in foods and to those forms added to foods. The Panel considers that sugar beet fibre is sufficiently characterised in relation to the claimed effect. The claimed effect is “decreasing intestinal transit time”. The target population proposed by the applicant is people who want to improve or maintain normal bowel function. The Panel considers that decreasing intestinal (orofaecal) transit time may be a beneficial physiological effect. The applicant provided four human studies as pertinent to the health claim. The Panel considers that no conclusion can be drawn from three studies for the scientific substantiation of the claim owing to methodological weaknesses whereas one human intervention study showed no effect of the consumption of sugar beet fibre on decreasing intestinal (orofaecal) transit time. In weighing the evidence the Panel took into account that one human study from which conclusions could be drawn for the scientific substantiation of the claim showed no effect of sugar beet fibre on intestinal (orofaecal) transit time. The Panel concludes that a cause and effect relationship has not been established between the consumption of sugar beet fibre and decreasing intestinal transit time. © European Food Safety Authority, 201

Online Research Database In Technology

Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to sugar beet fibre and decreasing intestinal transit time pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Following an application from Cargill Incorporated submitted pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to barley beta-glucans and lowering of blood cholesterol and reduced risk of (coronary) heart disease, referring to disease risk reduction and including a request for the protection of proprietary data. The food constituent that is the subject of the health claim, barley beta-glucans, is sufficiently characterised. Lowering blood LDL-cholesterol concentration is a beneficial physiological effect by decreasing the risk of coronary heart disease. The applicant identified a total of 16 references as being pertinent to the health claim. These references comprised three meta-analyses, 10 human intervention studies, two animal studies and one mechanistic study. In weighing the evidence, the Panel took into account that one meta-analysis including 11 RCTs and one additional RCT which investigated the effects of barley beta-glucans at doses of at least 3 g/day showed a decrease in total and LDL-cholesterol concentrations in both normo- and hypercholesterolaemic subjects, and that the mechanism by which barley beta-glucans could exert the claimed effect is biologically plausible and supported by the animal studies provided. The Panel concludes that a cause and effect relationship has been established between the consumption of barley beta-glucans and the lowering of blood LDL-cholesterol concentrations. The following wording reflects the scientific evidence: “Barley beta-glucans have been shown to lower/reduce blood cholesterol. High cholesterol is a risk factor in the development of coronary heart disease”. At least 3 g of barley beta-glucans should be consumed per day in order to obtain the claimed effect. The target population is adults who want to lower their blood cholesterol concentrations. © European Food Safety Authority, 201

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to barley beta-glucan and lowering of blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006

null null

Crossref

Scientific Opinion on the substantiation of a health claim related to sugar beet fibre and decreasing intestinal transit time pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Scientific Opinion on the substantiation of a health claim related to barley beta-glucans and lowering of blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006

http://orbit.dtu.dk/ws/files/6355317/prod11324397998769.Scientific.pdf

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to barley beta-glucan and lowering of blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006

Abstract

Similar works

Full text

Available Versions

Online Research Database In Technology

Online Research Database In Technology

Crossref

Crossref